FDA Manufacturing Supplement Proposal To Be Discussed By Advisory Cmte.
Executive Summary
FDA's Pharmaceutical Sciences Advisory Committee will discuss the agency's proposal to reduce post-approval manufacturing change reporting requirements for "qualified " products during a Nov. 15-17 meeting.
You may also be interested in...
FDA Risk-Based CMC Review Will Reduce Filing Requirements
FDA's Center For Drug Evaluation & Research is relying on risk management concepts to reduce chemistry, manufacturing and control submission requirements.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011